teaser
The third joint BioIndustry Association (BIA) and Medicines and Healthcare Products Regulatory Agency (MHRA) conference on 5 June 2013 will provide regulatory and bioscience industry views on supporting innovation in the development and regulation of biopharmaceuticals.
The conference will be the ideal place to hear the very latest thinking from the MHRA’s senior experts and industry-leading speakers on topics including state-of-play and future trends for supporting science and innovation in the development and regulation of medicines; how the expanded MHRA remit can benefit its stakeholders; exploring regulatory flexibilities within existing EU legislation to stimulate innovation; and innovative approaches to pharmacovigilance and lifecycle management.
Confirmed speakers at the conference are:
- Sir Gordon Duff, Chairman of MHRA
- Dr Will Dere, International Chief Medical Officer and Senior Vice President, Global Development, Amgen
- Dr Stephen Inglis, Director of NIBSC
- Dr John Parkinson, Director of CPRD
- Fiona Reekie, Director of Regulatory Intelligence, Europe and Global Emerging Markets, Biogen Idec
- Dr Daniel O’Connor, Medical Assessor, Licensing Division, MHRA
- James Matcham, Director Biostatistics, Amgen
- Dr David Wright, Deputy Unit Manager, Licensing Division, MHRA
- Ian Rees, Expert GMP Inspector, MHRA
- Dr Philip Minor, NIBSC
- Dr Philip Bryan, Unit Manager, Vigilance and Risk Management of Medicines, MHRA
- Dr Dina Tresnan, Senior Director, Worldwide Safety Surveillance and Risk Management, Pfizer
- Dr David Gillen, Medical Director, Celgene
Dr Ian Hudson, MHRA, Director of Licensing, Vice-Chair of EMA’s Committee for Medicinal Products for Human Use (CHMP) and conference co-chair, said:
“This is an excellent opportunity for the agency to share their knowledge and expertise at this one day conference on 5 June with the BioIndustry Association. We’re looking forward to providing advice and assistance to people who are developing innovative products or exploring innovative approaches within the biopharmaceutical industry.”
Alan Morrison, Vice President, International Regulatory Affairs and Safety, Amgen, Chairman of BIA’s Regulatory Affairs Advisory Committee and conference co-chair, said:
“The event will build on the successes of the BIA’s previous joint conferences with MHRA and provide an excellent opportunity for industry to learn about latest developments from the regulator and for the regulator to learn about advances in biopharmaceutical innovation from within the industry.”
